000276821 001__ 276821
000276821 005__ 20250323000853.0
000276821 0247_ $$2doi$$a10.1007/s11682-024-00952-0
000276821 0247_ $$2pmid$$apmid:39443362
000276821 0247_ $$2ISSN$$a1931-7557
000276821 0247_ $$2ISSN$$a1931-7565
000276821 0247_ $$2altmetric$$aaltmetric:169695704
000276821 037__ $$aDZNE-2025-00334
000276821 041__ $$aEnglish
000276821 082__ $$a150
000276821 1001_ $$aZilioli, Alessandro$$b0
000276821 245__ $$aUnveiling the hippocampal subfield changes across the Alzheimer's disease continuum: a systematic review of neuroimaging studies.
000276821 260__ $$aNew York, NY [u.a.]$$bSpringer$$c2025
000276821 3367_ $$2DRIVER$$aarticle
000276821 3367_ $$2DataCite$$aOutput Types/Journal article
000276821 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1742213031_2880$$xReview Article
000276821 3367_ $$2BibTeX$$aARTICLE
000276821 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276821 3367_ $$00$$2EndNote$$aJournal Article
000276821 520__ $$aStudies exploring the hippocampal subfield atrophy in Alzheimer's disease (AD) have shown contradictory results. This review aims to disentangle such heterogeneity by investigating the dynamic changes of hippocampal subfields across the AD continuum. We systematically searched the PubMed and EMBASE databases for case-control studies. Selected studies included investigations of biomarker-based amyloid status and reported data on hippocampal subfield atrophy using advanced MRI techniques. Twelve studies were included. Despite high heterogeneity, a distinguishable pattern of vulnerability of hippocampal subfields can be recognized from the cognitively unimpaired phase to the dementia stage, shedding light on hippocampal changes with disease progression. Consistent findings revealed atrophy in the subiculum and presubiculum, along with a potential increase in volume in the cornu ammonis (CA) among the cognitively unimpaired group, a feature not observed in patients experiencing subjective cognitive decline. Atrophy in the subiculum, presubiculum, CA 1-4, and the dentate gyrus characterized the mild cognitive impairment stage, with a more pronounced severity in the progression to dementia.
000276821 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276821 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276821 650_7 $$2Other$$aAlzheimer’s disease continuum
000276821 650_7 $$2Other$$aHippocampal subfields
000276821 650_7 $$2Other$$aHippocampal volume and surface
000276821 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000276821 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000276821 650_2 $$2MeSH$$aHumans
000276821 650_2 $$2MeSH$$aHippocampus: pathology
000276821 650_2 $$2MeSH$$aHippocampus: diagnostic imaging
000276821 650_2 $$2MeSH$$aNeuroimaging: methods
000276821 650_2 $$2MeSH$$aAtrophy
000276821 650_2 $$2MeSH$$aDisease Progression
000276821 650_2 $$2MeSH$$aMagnetic Resonance Imaging: methods
000276821 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000276821 7001_ $$aPancaldi, Beatrice$$b1
000276821 7001_ $$0P:(DE-2719)9001499$$aBaumeister, Hannah$$b2$$udzne
000276821 7001_ $$aBusi, Gabriele$$b3
000276821 7001_ $$00000-0001-8730-4397$$aMisirocchi, Francesco$$b4
000276821 7001_ $$aMutti, Carlotta$$b5
000276821 7001_ $$aFlorindo, Irene$$b6
000276821 7001_ $$aMorelli, Nicola$$b7
000276821 7001_ $$aMohanty, Rosaleena$$b8
000276821 7001_ $$0P:(DE-2719)2812972$$aBerron, David$$b9$$udzne
000276821 7001_ $$aWestman, Eric$$b10
000276821 7001_ $$aSpallazzi, Marco$$b11
000276821 773__ $$0PERI:(DE-600)2377165-3$$a10.1007/s11682-024-00952-0$$gVol. 19, no. 1, p. 253 - 267$$n1$$p253 - 267$$tBrain imaging and behavior$$v19$$x1931-7557$$y2025
000276821 8564_ $$uhttps://pub.dzne.de/record/276821/files/DZNE-2025-00334_Restricted.pdf
000276821 8564_ $$uhttps://pub.dzne.de/record/276821/files/DZNE-2025-00334_Restricted.pdf?subformat=pdfa$$xpdfa
000276821 909CO $$ooai:pub.dzne.de:276821$$pVDB
000276821 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001499$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000276821 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812972$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000276821 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276821 9141_ $$y2025
000276821 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000276821 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-11$$wger
000276821 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN IMAGING BEHAV : 2022$$d2024-12-11
000276821 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000276821 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000276821 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000276821 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000276821 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000276821 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000276821 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000276821 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-11
000276821 9201_ $$0I:(DE-2719)5000070$$kAG Berron$$lClinical Cognitive Neuroscience$$x0
000276821 980__ $$ajournal
000276821 980__ $$aVDB
000276821 980__ $$aI:(DE-2719)5000070
000276821 980__ $$aUNRESTRICTED